WBSCR28 Inhibitors
WBSCR28 inhibitors refer to a class of chemical compounds that specifically target and inhibit the activity of the enzyme WBSCR28, also known as Williams-Beuren syndrome chromosome region 28. The precise biochemical function of WBSCR28 is not entirely elucidated, but it is known to play a role in cellular processes due to its location within a region that is often deleted in individuals with Williams-Beuren syndrome, a complex developmental disorder. As inhibitors, these compounds interact with the active site or other critical regions of the enzyme, effectively reducing or eliminating its normal activity. The mechanism of inhibition may involve direct interaction with the catalytic site of the enzyme, altering its conformation, competing with substrate molecules, or other processes that result in the impediment of the enzyme's function.
The development and study of WBSCR28 inhibitors are rooted in the pursuit of understanding the fundamental biological pathways in which WBSCR28 is involved. The enzyme's activity is associated with various cellular functions including, but not limited to, the regulation of gene expression and the modulation of metabolic pathways. By inhibiting WBSCR28, researchers can observe the phenotypic consequences in cellular or animal models, which contributes to a deeper comprehension of the enzyme's role in biological systems. The chemical structure of these inhibitors is diverse, reflecting the different strategies employed to achieve selective binding and inhibition of the enzyme. Studies involving WBSCR28 inhibitors are primarily focused on elucidating the enzyme's function, exploring its interaction with other cellular components, and understanding the broader biological networks in which it participates.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that can suppress protein synthesis and cell growth. Since WBSCR28 is a protein that may be involved in these processes, inhibiting mTOR could reduce the functional activity of WBSCR28 by limiting its role in cell growth. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that disrupts the PI3K/Akt/mTOR signaling pathway. By inhibiting this pathway, LY294002 might indirectly decrease the activity of WBSCR28, assuming WBSCR28 is downstream or associated with this pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another potent PI3K inhibitor. It leads to the downregulation of the PI3K/Akt/mTOR pathway, which could indirectly decrease the activity of WBSCR28 if it is functionally connected to this pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that blocks the MAPK/ERK pathway. If WBSCR28 is involved in this pathway or its activity is modulated by it, PD98059 would lead to a decrease in WBSCR28 functional activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that could indirectly affect WBSCR28 activity by inhibiting the p38 MAPK pathway, which is involved in stress responses, cytokine production, and cell differentiation processes. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor which could potentially reduce the functional activity of WBSCR28 by modulating the JNK signaling cascade that may be implicated in the processes where WBSCR28 is involved, such as apoptosis or cellular stress responses. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are upstream regulators of ERK1/2 in the MAPK pathway. By inhibiting MEK1/2, U0126 could therefore decrease the functional activity of WBSCR28 if it is influenced by the MAPK signaling. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts protein transport by inhibiting the ADP-ribosylation factor (ARF), which could affect WBSCR28 if it relies on protein transport mechanisms for its activity or localization. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Cycloheximide inhibits protein biosynthesis at the translation step, which could lead to a general decrease in WBSCR28 levels and thus its activity, assuming it has a rapid turnover and is continuously synthesized. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D is an inhibitor of RNA polymerase, which prevents RNA synthesis. This could lead to a decrease in WBSCR28 activity by preventing the transcription of its mRNA. | ||||||